AI creates enterprise consequences faster than functionally organized institutions can govern them. The complete AI value chain crosses six domains: clinical value and patient safety, AI and product engineering, security, legal and governance, operations and implementation, capital allocation and fundraising, and commercial execution and ROI. Every function can perform competently while the combined system fails, because the highest-consequence risks live in the seams between them. Holding that whole is general management, and the institutions that once built general managers dismantled the machinery decades ago. There is no labor market to buy them from. For investors, the diligence question is not whether expertise is present but whether one accountable owner can convert those specialties into one sustainable operating result. A general-management deficit shows up later as false ROI and fragmented safety. Institutions must build these leaders themselves.
Artificial intelligence is creating enterprise-level consequences faster than functionally organized institutions can recognize, govern, or absorb them. The constraint is no longer simply technical capability. It is the shortage of leaders who can integrate medicine, engineering, cybersecurity, law, finance, operations, workforce design, capital, commercialization, and institutional accountability into one operating result.
That is the work of general management. AI increases the demand for it precisely when the institutions that once produced general managers have largely stopped doing so.
AI does not stay inside the function that bought it
Traditional technologies could often be assigned to a department. IT implemented the system, security protected it, clinicians used it, compliance reviewed it, and finance measured the return.
AI does not respect those boundaries. It influences decisions, changes workflows, reallocates labor, generates evidence, creates new failure modes, and continues changing after deployment.
The complete AI value chain crosses six domains:
- Clinical value and patient safety: whether the system improves care without creating unacceptable clinical risk.
- AI and product engineering: whether the product, models, data, infrastructure, and integrations work reliably.
- Security, legal, and governance: whether the system is protected, controlled, defensible, and operated within institutional obligations.
- Operations and implementation: whether workflows, escalation paths, staffing, training, and exception handling work in practice.
- Capital allocation and fundraising: whether the company can finance the right milestones and direct scarce resources to the risks that determine success.
- Commercial execution and ROI: whether there is a real buyer, budget, procurement path, implementation model, and measurable return.
Each function can perform its assigned work competently while the combined system fails. The highest-consequence risks live in the seams: between the model and the workflow, the vendor and the institution, the clinical judgment and the technical control, the promised automation and the human labor required to keep it safe.
Why AI specifically demands general management
AI introduces decisions that expertise alone cannot resolve. Someone must decide:
- Whether the organization should deploy the system at all
- Which risks are acceptable in exchange for which benefits
- How work, authority, and accountability will change
- Who can override or stop the system
- What evidence is sufficient for continued operation
- Who owns a failure that crosses several functions or vendors
- Whether the promised return remains real after integration, monitoring, exception handling, and workforce costs
These are general-management decisions. They require a leader who can hold competing objectives together, assign decision rights, force unresolved dependencies into view, and remain accountable for the combined outcome.
AI makes this especially urgent for four reasons.
AI scales decisions. A weak process that once affected a few cases can be reproduced across thousands of patients, employees, or transactions.
AI changes after implementation. Models, data, integrations, threats, vendors, and user behavior evolve. Approval at launch is not control in production.
AI conceals operational labor. Apparent automation often depends on review, escalation, correction, monitoring, and exception handling. Those costs disappear across departmental budgets until failure makes them visible.
AI redistributes authority. A tool can quietly change who makes a decision, what evidence they see, and who is blamed, even when the formal organization chart has not changed.
AI creates enterprise-level consequences faster than functionally organized institutions can recognize or govern them.
AI must be financed, commercialized, implemented, and governed as one system
Safe AI that cannot be financed, purchased, implemented, and sustained will not reach patients or produce durable value.
Fundraising, capital allocation, and commercial execution are not downstream business activities. They shape which product gets built, what evidence is produced, which controls are funded, how long the company can support institutional adoption, and whether its economics survive contact with production.
Fundraising determines which milestones the company can reach and which capital partners influence its direction. Capital allocation determines whether money reaches evidence, infrastructure, security, implementation, and monitoring rather than only model development and sales. Commercial execution determines whether the product has a real accountable buyer, budget, procurement path, pricing model, implementation capacity, and proof sufficient for renewal and expansion.
A technically excellent AI company can fail because it raises the wrong capital, spends ahead of evidence, confuses users with buyers, underprices implementation, or cannot convert pilots into production.
A commercially successful company can also externalize safety, integration, and operating costs onto its customers.
The general manager must prevent both failures by holding company formation, product development, institutional adoption, patient safety, and enterprise value together.
An AI general manager holds the complete value chain together, from capital formation and product development through institutional deployment, patient safety, measurable return, and continuing accountability.
What must be held across the entire chain
Five responsibilities cut across all six domains and cannot be resolved within any one specialty.
Strategy and market selection
The general manager must decide which problems are worth solving, for whom, and why the organization has a credible right to win. Fundraising and sales cannot substitute for coherent strategy.
Data, infrastructure, and vendor dependencies
AI performance depends on data quality, cloud services, integrations, third-party models, supply-chain continuity, and fallback capability. These dependencies often sit outside the nominal AI team but determine whether the combined system works in production.
Workforce and workflow redesign
AI changes jobs, authority, supervision, cognitive burden, staffing, escalation paths, and accountability. Training people to use a tool is not the same as redesigning the operating model around it.
Evidence and lifecycle monitoring
The accountable owner must determine what evidence supports deployment, how performance will be monitored, and what triggers reassessment, intervention, rollback, or retirement. Initial validation is not continuing accountability.
Decision rights and executive sponsorship
The accountable owner requires sufficient authority, budget, executive access, and stopping power to carry the combined outcome. Accountability without authority is exposure, not management.
AI requires one accountable owner to integrate strategy, capital, product, infrastructure, expertise, workforce, commercialization, evidence, and institutional consequences across the full lifecycle.
General managers were built, not found
For much of the twentieth century, large institutions deliberately developed general managers. High-potential leaders moved across functions, operating units, geographies, and levels of responsibility. They learned finance, operations, product, sales, labor, technology, and customer consequence by carrying progressively larger responsibility for results.
Long executive apprenticeships, internal labor markets, rotational assignments, and patient promotion systems created leaders who could integrate the enterprise. Profit-and-loss responsibility gave them a forcing function: they could not declare success in one function while the whole business failed.
The system was imperfect and access to it was often inequitable. But its core operating logic was sound. Breadth was developed through repeated exposure to real consequences under the supervision of leaders who had already carried the whole.
Why the pipeline disappeared
- Careers became more mobile, reducing the employer's expected return on years of leadership development.
- Companies flattened management layers and eliminated many deputy, rotation, and apprenticeship roles where integration was learned.
- Functional specialization became the dominant path to authority, compensation, credentials, and professional identity.
- Outsourcing removed the operational exposure through which leaders learned how complete systems actually work.
- Short-term financial pressure rewarded immediate functional output over slow cross-functional formation.
- Digital transformation separated business ownership from technical implementation.
- Governance and compliance multiplied responsibilities without creating a corresponding operating owner.
- Executive recruiting encouraged institutions to buy finished leaders from the market instead of building them internally.
There is now no sufficiently mature external labor market from which healthcare and technology companies can simply purchase the number of general managers AI requires. The institutional machinery that would have created them was dismantled before the demand became obvious.
The incentives run against the work
Specialists receive recognizable titles, credentials, peer groups, conferences, promotion paths, and measurable accomplishments. General managers inherit dependencies they do not control and reconcile competing definitions of success. Their most important output is often the absence of failure.
Seam ownership is accountability without glory. When integration works, it is nearly invisible. When it fails, the person holding the seam becomes the address for blame.
The strongest candidates can make an individually rational decision to remain inside a respected specialty rather than accept broader accountability without matching authority, resources, recognition, or economic participation.
Organizations compound the problem when they demand enterprise integration without supplying those conditions. The people most capable of holding the whole are asked to accept greater exposure with fewer visible rewards than they could earn inside a respected specialty. The predictable result is that scarce general-management capacity remains undeveloped, exits, or is consumed as hidden labor.
Why this becomes a patient-safety and ROI crisis
Without a general manager, no one owns whether the combined AI system produces value safely.
Clinical benefit may be assessed separately from infrastructure cost. Security controls may be evaluated separately from workflow burden. Vendor performance may be measured separately from exception handling. Labor displacement may be counted as savings before replacement work, supervision, escalation, and liability are understood.
The result is false ROI and fragmented safety. Benefits are credited centrally while costs and failures are distributed across departments. Patient harm, workforce overload, technical fragility, and financial underperformance appear later as separate problems even though they came from the same unmanaged system.
AI does not eliminate management. It increases the need for its rarest form: accountable integration across the whole lifecycle.
A leadership team may contain distinguished clinicians, engineers, cybersecurity leaders, lawyers, operators, financial executives, and commercial leaders while still lacking the capability to integrate their work into one operating result.
High-consequence AI investments often fail through transfer. The company transfers hidden operational debt to the institution, or the institution transfers unowned integration debt back onto the investment. Either direction destroys value, which is why this diligence protects both sides of the transaction.
For investors, the relevant question is not whether expertise is present. It is whether the company can demonstrate:
- One accountable owner for the complete AI outcome
- Leadership experience spanning multiple parts of the value chain
- Decision rights sufficient to resolve cross-functional tradeoffs
- Capital allocation aligned with evidence, infrastructure, security, implementation, monitoring, and commercialization
- Realistic cost and margin assumptions that include hidden operational labor
- A credible path from product development through procurement, production, renewal, and expansion
- A plan to develop and retain additional general-management capacity
A general-management deficit can affect burn, financing requirements, time to revenue, customer retention, liability exposure, enterprise value, and the credibility of management forecasts.
Any deficiency remains the company's responsibility to address. The investor determines whether the evidence is sufficient and whether the resulting gap changes investment size, structure, timing, conditions, remediation funding, or viability.
Investors should not assume that a collection of excellent specialists constitutes a capable AI management system. The diligence question is whether someone has the range, authority, incentives, and demonstrated judgment to convert those specialties into one sustainable operating result.
You build them yourself
Every technology company and healthcare institution must rebuild general-management formation as an internal capability. It must identify people with the capacity and appetite to hold the whole, expose them to consequential operating assignments, and give them progressively greater authority for integrated outcomes.
Institutions should:
- Rotate candidates through clinical or customer operations, product and technology, security and governance, capital allocation, fundraising, and commercial execution.
- Give them real outcome responsibility rather than observation-only exposure.
- Pair accountability with decision rights, budget, executive access, and the authority to stop unsafe deployment.
- Reward enterprise outcomes, including avoided failure and resolved dependencies, not only visible functional production.
- Create scarce sponsorship from senior leaders willing to put reputation and opportunity behind the strongest candidates.
- Treat general-management development as succession infrastructure, not optional professional enrichment.
A strong specialist is not transformed into a general manager by changing a title. General management is built through repeated responsibility for the whole, under real constraints, with consequences that cannot be delegated away.
Our role and boundary
The Trustworthy Technology & Innovation Consortium (TTIC) will always have room for exceptional general-management profiles who can integrate medicine, technology, security, governance, operations, capital, commercialization, and institutional consequence. These leaders are essential to TTIC's ability to connect accredited standards, technical controls, clinical safety, organizational accountability, and production evidence.
TTIC offers a high-performance environment in which such leaders can contribute, learn with peers, and strengthen the field through consequential work. Participation can reveal and deepen general-management capacity because the work itself crosses traditional professional boundaries.
TTIC does not build general managers for the industry, provide them to member organizations, operate as a staffing pipeline, or assume responsibility for solving a company's internal management deficit. TTIC cannot carry the integration load that belongs to the institution deploying or commercializing the technology.
Every technology company and healthcare institution must identify, develop, empower, fund, and retain its own general-management capability. TTIC can define the problem, establish requirements, convene leaders capable of addressing it, and create a setting where exceptional integrators contribute. It cannot substitute for management inside the companies and institutions that own the outcomes.
The institutional decision
Organizations can continue purchasing and building AI while leaving integration ownerless, or they can rebuild the management capacity required to convert technical capability into safe, durable value.
The first path produces pilots, fragmented controls, hidden labor, false returns, and recurring surprises. The second produces accountable operating systems.
The central question is no longer whether AI will enter the institution. It is whether the institution will build leaders capable of holding what AI changes.
TTIC provides practitioner-informed requirements and educational resources. Investors remain responsible for diligence, investment judgment, risk interpretation, and every capital decision. Companies remain responsible for remediation and execution. TTIC does not recommend investments, endorse companies, score candidates for investors, or participate in investment committee decisions.
Related TTIC perspective
Sherri Douville
Founder & Chair, Trustworthy Technology & Innovation Consortium